Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156403 | 0.81 | NR4A2 (0.49) | TSHRMAPTLMNAKDM4E | |
| SCHEMBL6082830 | 0.81 | TSHR (0.52) | GABRA1GABRB2GABRB1GABRA3KMT2A | |
| SCHEMBL1752519 | 0.80 | GRM1 (0.59) | GABRA1GABRB2KMT2AMEN1TSHR | |
| SCHEMBL4045529 | 0.78 | TSHR (0.61) | KMT2AMEN1TSHRCLEC4MALDH1A1 | |
| SCHEMBL12529489 | 0.77 | GRM1 (0.53) | GABRA1GABRB2KMT2AMEN1TSHR | |
| SCHEMBL1156113 | 0.77 | JAK2 (0.52) | GABRA1GABRB2GABRB1GABRA3TSHR | |
| SCHEMBL3138229 | 0.76 | GRM1 (0.49) | GABRA1GABRB2KMT2AMEN1TSHR | |
| SCHEMBL1079651 | 0.76 | KMT2A (0.50) | GABRA1GABRB2GABRB1GABRA3KMT2A | |
| SCHEMBL30717961 | 0.75 | KMT2A (0.55) | GABRA1GABRB2GABRB1GABRA3KMT2A | |
| SCHEMBL28944544 | 0.75 | NOTUM (0.50) | KMT2AMEN1ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4317133-B1 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-12527763-B2 | Pyrrole amide compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-01-20 | — | — | US | disclosed |
| US-20240376051-A1 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-114456098-B | Preparation method of medicine Ai Shali ketone for treating diabetic nephropathy | 大连理工大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-118063372-A | Preparation method of pyrrole amide compound and intermediate thereof | 年衍药业(珠海)有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4317133-A1 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-115141132-B | Crystal forms of pyrrole amide compound, preparation method and application thereof | 年衍药业(珠海)有限公司 | 2023-05-19 | — | — | CN | disclosed |
| WO-2022206666-A1 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 广东东阳光药业有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115141132-A | Crystal form of pyrrole amide compound and preparation method and application thereof | 年衍药业(珠海)有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220211665-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | GABRA1 66/4885GABRB2 59/4885GABRB1 58/4885 |
| US-12527763-B2 | Pyrrole amide compound and use thereof | NR3C2, AVPR2, MC2R | GABRA1 1496/4885GABRB2 890/4885GABRB1 1089/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | GABRA1 290/4885GABRB2 675/4885GABRB1 330/4885 |
| US-20220211665-A1 | PYRROLE AMIDE COMPOUND AND USE THEREOF | MC2R, NR3C2, AVPR2 | GABRA1 264/4885GABRB2 421/4885GABRB1 495/4885 |
| US-20240376051-A1 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | REN, CYP27A1, CYP4F11 | GABRA1 2493/4885GABRB2 3103/4885GABRB1 2853/4885 |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | NCOA1, NCOA2, NCOA3 | GABRA1 197/4885GABRB2 242/4885GABRB1 253/4885 |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | GABRA1 1814/4885GABRB2 2113/4885GABRB1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.